Skip to Content

Join the 'Crohn's Disease - Maintenance' group to help and get support from people like you.

Crohn's Disease - Maintenance News

Scientists Spot Genes Behind Crohn's, Ulcerative Colitis

Posted 29 Jun 2017 by Drugs.com

THURSDAY, June 29, 2017 – Researchers say they've come closer to pinpointing genes linked with inflammatory bowel diseases such as Crohn's and ulcerative colitis. For the study, the investigators examined the genomes of nearly 68,000 people. Of the regions of the genome associated with inflammatory bowel disease (IBD), 18 could be traced to a single genetic variant with more than 95 percent certainty. "We have taken the biggest ever data set for IBD and applied careful statistics to narrow down to the individual genetic variants involved," said study co-author Dr. Jeffrey Barrett, from the Wellcome Trust Sanger Institute in the United Kingdom. "Now we have a clearer picture of which genes do and do not play a role in the disease. We are zooming in on the genetic culprits of IBD," he said in an institute news release. The findings could lead to improved effectiveness of current ... Read more

Related support groups: Prednisone, Methylprednisolone, Crohn's Disease, Prednisolone, Ulcerative Colitis, Cortisone, Hydrocortisone, Medrol, Dexamethasone, Triamcinolone, Crohn's Disease - Maintenance, Betamethasone, Inflammatory Bowel Disease, Budesonide, Ulcerative Colitis - Active, Decadron, Crohn's Disease - Acute, Entocort, Ulcerative Colitis - Maintenance, Solu-Medrol

FDA Approves Renflexis (infliximab-abda), a Biosimilar to Remicade

Posted 27 Apr 2017 by Drugs.com

INCHEON, Korea – April 24, 2017 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Renflexis (infliximab-abda), a biosimilar referencing Remicade®i (infliximab), across all eligible indications. In the US, Renflexis is indicated for reducing signs and symptoms in patients with adult and pediatric Crohn’s disease, adult ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, and for the treatment of adult plaque psoriasis. Renflexis is the first Samsung Bioepis product approved for marketing in the United States (US). “Since our company was established five years ago, we have strived day in and day out to realize the promise of biosimilars for patients across the United States by offering them treatment options at a lower cost. We hope this regulatory milestone will bring us a step closer to achievin ... Read more

Related support groups: Rheumatoid Arthritis, Crohn's Disease, Remicade, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Plaque Psoriasis, Ulcerative Colitis - Active, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Infliximab, Renflexis

New Meds Make Inroads Against Crohn's Disease

Posted 13 Apr 2017 by Drugs.com

THURSDAY, April 13, 2017 – Fewer Americans with Crohn's disease are ending up in the hospital than in the past, according to a new federal study. Crohn's is a chronic inflammatory bowel disorder that often leads to surgery for most with the disease. Hospitalization rates for Crohn's disease remained stable in the United States between 2003 and 2013. That's a change from a study done from 1998 to 2004 that saw more than 4 percent increases in Crohn's hospitalizations each year, researchers with the U.S. Centers for Disease Control and Prevention said. The stable hospital rates are likely due to the 1998 introduction of a new class of biologic drugs. Examples of these medications used to treat Crohn's disease include: adalimumab (Humira), infliximab (Remicade), certolizumab (Cimzia) and ustekinumab (Stelara), according to the U.S. National Institute of Diabetes and Digestive and Kidney ... Read more

Related support groups: Humira, Crohn's Disease, Remicade, Ulcerative Colitis, Crohn's Disease - Maintenance, Inflammatory Bowel Disease, Ulcerative Colitis - Active, Cimzia, Stelara, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Infliximab, Adalimumab, Ustekinumab, Inflectra, Amjevita, Certolizumab

Common Virus May Be Linked to Heart Disease, Diabetes in Some Women

Posted 23 Feb 2017 by Drugs.com

THURSDAY, Feb. 23, 2017 – A common virus may make some women more susceptible to both heart disease and type 2 diabetes, a new study suggests. Scientists at the University of California, San Francisco found normal-weight women under age 50 who were infected with cytomegalovirus (CMV) were more likely to have metabolic syndrome than their peers. Metabolic syndrome is a collection of risk factors for heart disease and diabetes that includes excess belly fat, unhealthy cholesterol levels, high blood pressure and high blood sugar levels. CMV, a herpes virus, is believed to infect roughly half of the U.S. population over the age of 40. Typically there are no symptoms unless the person's immune system is weakened. Ironically, obese women infected with CMV were less likely to have metabolic syndrome than obese women not infected with the virus, the researchers found. However, obese women were ... Read more

Related support groups: Diabetes, Type 2, Heart Disease, High Cholesterol, Crohn's Disease, Insulin Resistance, Crohn's Disease - Maintenance, Pre-Diabetes, Inflammatory Bowel Disease, Crohn's Disease - Acute, Viral Infection, Cytomegalovirus (CMV) Infection, Ulcerative Proctitis, Ischemic Heart Disease, CMV Pneumonia, CMV Retinitis, CMV Gastroenteritis

Special Diet May Be Boon for Kids With Crohn's, Colitis

Posted 10 Jan 2017 by Drugs.com

MONDAY, Jan. 9, 2017 – Children with Crohn's disease and ulcerative colitis may be able to achieve relief without medications by eating a special diet, a small study suggests. The diet includes non-processed foods, such as fruits, vegetables, meats and nuts. Over 12 weeks, the diet appeared to ease all signs of these inflammatory bowel diseases in eight of the 10 affected children, researchers report. "The study shows that without other intervention, other changes, we can improve individuals' clinical as well as laboratory markers," said study author Dr. David Suskind. He's a professor of pediatrics and director of clinical gastroenterology at Seattle Children's Hospital. "I'm not surprised," Suskind added, "primarily because preliminary studies ... opened our eyes to the idea that diet had an impact." Inflammatory bowel disease (IBD) affects about 1.6 million Americans, according to ... Read more

Related support groups: Crohn's Disease, Colitis, Dietary Supplementation, Ulcerative Colitis, Asacol, Crohn's Disease - Maintenance, Creon, Inflammatory Bowel Disease, Sulfasalazine, Ulcerative Colitis - Active, Pentasa, Lialda, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Lactaid, Apriso, Mesalamine, Pancrease, Zenpep, Canasa

Drug Stelara May Ease Crohn's Disease

Posted 18 Nov 2016 by Drugs.com

THURSDAY, Nov. 17, 2016 – People with moderate to severe Crohn's disease who haven't responded to other treatments may benefit from the drug ustekinumab (Stelara), a new study suggests. Stelara is a monoclonal antibody that blocks the action of the inflammatory agents interleukin-12 and interleukin-23. The drug had been approved for the treatment of psoriasis and is now approved for treating Crohn's disease as well. Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract. Crohn's usually affects the end of the small bowel and the beginning of the colon. But it may affect any part of the gastrointestinal tract, from the mouth to the anus, according to the Crohn's and Colitis Foundation of America (CCFA). Crohn's can cause diarrhea, rectal bleeding, an urgent need to move the bowels, stomach cramps, pain and constipation, the CCFA says. "Stelara is effective for ... Read more

Related support groups: Humira, Crohn's Disease, Remicade, Crohn's Disease - Maintenance, Cimzia, Stelara, Crohn's Disease - Acute, Ustekinumab

Study Identifies Genetic Subtypes of Crohn's Disease

Posted 14 Oct 2016 by Drugs.com

FRIDAY, Oct. 14, 2016 – Crohn's disease appears to have at least two distinct genetic subtypes, which could explain why the condition is so hard to treat, a new study suggests. "The one-treatment-fits-all approach doesn't seem to be working for Crohn's patients," said study co-senior author Dr. Shehzad Sheikh. He's an assistant professor in the departments of medicine and genetics at the University of North Carolina School of Medicine. "It's plausible that this is because only a subset of patients has the type of disease that responds to standard therapy, whereas, for the rest of the patients, we're really not hitting the right targets," Sheikh said in a university news release. Crohn's is a chronic inflammatory disorder of the intestinal tract. The most common symptoms are diarrhea, stomach cramps and weight loss. The course and severity of the disease vary widely from patient to ... Read more

Related support groups: Humira, Crohn's Disease, Asacol, Crohn's Disease - Maintenance, Inflammatory Bowel Disease, Sulfasalazine, Pentasa, Lialda, Stelara, Crohn's Disease - Acute, Apriso, Mesalamine, Canasa, Azulfidine, Diagnosis and Investigation, Asacol HD, Delzicol, Sulfazine, Rowasa, Azulfidine EN-tabs

Amjevita OK'd to Treat Inflammatory Diseases

Posted 27 Sep 2016 by Drugs.com

MONDAY, Sept. 26, 2016 – Amjevita (adalimumab-atto) – a biosimilar drug similar to the popular anti-inflammatory drug Humira – has been approved by the U.S. Food and Drug Administration. Amjevita has been approved for moderate-to-severe rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis (an arthritis that affects the spine); Crohn's disease; ulcerative colitis; plaque psoriasis and juvenile idiopathic arthritis, the FDA said in a news release. Biological drugs are generally derived from a living organism and can come from many sources, including humans, animals, microorganisms or yeast, the FDA said. A biosimilar drug is a biological product that's sanctioned after its maker proves it is "highly similar" to an already-approved biologic drug. The manufacturer of the biosimilar drug must prove that the product has "no clinically meaningful differences" in safety, purity ... Read more

Related support groups: Rheumatoid Arthritis, Humira, Crohn's Disease, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Plaque Psoriasis, Ulcerative Colitis - Active, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Juvenile Idiopathic Arthritis, Adalimumab, Amjevita

FDA Approves Amjevita (adalimumab-atto), a Biosimilar to Humira

Posted 26 Sep 2016 by Drugs.com

September 23, 2016 – The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases. Amjevita is approved for the following indications in adult patients: moderately to severely active rheumatoid arthritis; active psoriatic arthritis; active ankylosing spondylitis (an arthritis that affects the spine); moderately to severely active Crohn’s disease; moderately to severely active ulcerative colitis; and moderate to severe plaque psoriasis. Amjevita is also indicated for moderately to severely active polyarticular juvenile idiopathic arthritis in patients four years of age and older. Health care professionals should review the prescribing information in the labeling for detailed information about the approved uses. “This is the fourth FDA-approved biosimilar. The biosimilar pathway is still a new fr ... Read more

Related support groups: Rheumatoid Arthritis, Humira, Psoriasis, Crohn's Disease, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Plaque Psoriasis, Ulcerative Colitis - Maintenance, Adalimumab, Amjevita

Smoking Linked to Higher Relapse Risk After Surgery for Crohn's

Posted 2 Sep 2016 by Drugs.com

THURSDAY, Sept. 1, 2016 – Smoking increases the risk that Crohn's disease patients will have relapses after bowel surgery, new research suggests. The study included 240 Crohn's disease patients in the United Kingdom who were followed for three years after bowel surgery. Crohn's disease occurs when the immune system attacks the lining of the gut and bowel, and causes severe inflammation, the study authors noted. This can result in diarrhea, abdominal pain, nausea and reduced appetite. Patients are usually initially treated with drugs to suppress their immune system. But the study authors said that more than half of Crohn's patients eventually have surgery to remove the affected section of their bowel. However, surgery does not cure Crohn's, and relapses are common. According to the researchers from the University of Edinburgh in Scotland, smokers were much more likely than nonsmokers to ... Read more

Related support groups: Surgery, Smoking, Crohn's Disease, Smoking Cessation, Crohn's Disease - Maintenance, Crohn's Disease - Acute

Inflectra Approved as 'Biosimilar' to Remicade

Posted 7 Apr 2016 by Drugs.com

WEDNESDAY, April 6, 2016 – The U.S. Food and Drug Administration has approved its second-ever "biosimilar" drug, Inflectra, for adults with Crohn's disease, rheumatoid arthritis or chronic plaque psoriasis, among other prescribed uses. In a media release, the agency said Inflectra was biosimilar to Janssen Biotech's Remicade (infliximab), first licensed in 1998. A biosimilar drug is sanctioned based on its maker's ability to show that it is "highly similar" to an already-approved biological drug that is generally derived from a living organism, such as a person, animal, microorganism or yeast, the FDA said. The maker of a biosimilar drug also must prove that the product has no "clinically meaningful difference" in safety and effectiveness from the original drug, and that the newer product has only "minor differences in clinically inactive components" from the original. Inflectra's most ... Read more

Related support groups: Rheumatoid Arthritis, Psoriasis, Crohn's Disease, Remicade, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Plaque Psoriasis, Ulcerative Colitis - Active, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Infliximab, Inflectra

Health Tip: Get Enough Nutrients

Posted 14 Jan 2016 by Drugs.com

-- A nutritious diet is especially important for people with irritable bowel disease (IBD), since they may be at increased risk of malnutrition. The Crohn's and Colitis Foundation of America says possible benefits of a nutritious diet include: Fewer symptoms of IBD. Reduced risk of iron or calcium deficiency. Improved bone health. Healthier body weight. Better regulation of hormone levels in girls and women. Read more

Related support groups: Irritable Bowel Syndrome, Crohn's Disease, Crohn's Disease - Maintenance, Crohn's Disease - Acute

Stem Cell Transplants May Not Help Tough-to-Treat Crohn's, Study Says

Posted 15 Dec 2015 by Drugs.com

TUESDAY, Dec. 15, 2015 – Stem cell transplants seem no better than conventional therapy for Crohn's disease that hasn't responded to other treatments, a new study finds. The European study also found that for patients who cannot undergo surgery for the condition, stem cell transplants resulted in serious side effects, including infections. "In this group of the most resistant cases of Crohn's disease, stem cell transplant was an effective treatment, but it is not a miracle cure that could be applied to anyone with Crohn's disease, because it only seems to work in a minority of patients and the treatment is challenging and hazardous," said lead researcher Christopher Hawkey. He is a professor of gastroenterology at Queen's Medical Centre in Nottingham, England. For the study, Hawkey and colleagues randomly assigned 45 patients with Crohn's disease to transplants with their own stem ... Read more

Related support groups: Crohn's Disease, Asacol, Crohn's Disease - Maintenance, Sulfasalazine, Pentasa, Lialda, Crohn's Disease - Acute, Apriso, Mesalamine, Canasa, Azulfidine, Asacol HD, Delzicol, Diagnosis and Investigation, Sulfazine, Rowasa, Mesasal Enteric Coated, Azulfidine EN-tabs, Canasa Pac, Salofalk

Ultrasound Might Speed Up Digestive Drug Delivery: Animal Study

Posted 21 Oct 2015 by Drugs.com

WEDNESDAY, Oct. 21, 2015 – Ultrasound waves could be used to rapidly deliver drugs to the digestive system, new animal research suggests. This new approach to drug delivery might potentially benefit people with inflammatory bowel disease (IBD), such as Crohn's disease and ulcerative colitis. However, this new method of drug delivery hasn't yet been tested in humans. "With additional research, our technology could prove invaluable in both clinical and research settings, enabling improved therapies and expansion of research techniques applied to the [gastrointestinal] tract," said co-senior study author Daniel Blankschtein, a professor of chemical engineering at Massachusetts Institute of Technology (MIT) in Cambridge. "[Our study] demonstrates for the first time the active administration of drugs, including biologics, through the GI tract," he said in an MIT news release. The ... Read more

Related support groups: Crohn's Disease, Colitis, Ulcerative Colitis, Crohn's Disease - Maintenance, Inflammatory Bowel Disease, Ulcerative Colitis - Active, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Diagnosis and Investigation

Crohn's Disease Treatments for Kids May Not Get Gut Back to Normal

Posted 14 Oct 2015 by Drugs.com

WEDNESDAY, Oct. 14, 2015 – Current therapies for children with Crohn's disease don't fully restore healthy bacteria and fungi populations in their digestive systems, a new study shows. These findings suggest that treatments don't have to bring bacteria and other microbe levels back to normal levels in the gut to be useful. This knowledge could lead to new approaches for diagnosing and treating inflammatory bowel disease, according to the Oct. 14 study in the journal Cell Host & Microbe. "We show that microbes in the gut respond to treatment of inflammatory bowel disease in a much more complex way than has been previously appreciated," co-principal investigator Gary Wu, from the University of Pennsylvania in Philadelphia, said in a journal news release. "The results of our study provide information that could be used to track or predict disease, as well as new diet-based therapeutic ... Read more

Related support groups: Prednisone, Methylprednisolone, Crohn's Disease, Prednisolone, Cortisone, Hydrocortisone, Medrol, Dexamethasone, Triamcinolone, Asacol, Crohn's Disease - Maintenance, Betamethasone, Sulfasalazine, Budesonide, Pentasa, Decadron, Lialda, Crohn's Disease - Acute, Entocort, Solu-Medrol

Page 1 2 3 Next

Ask a Question

Further Information

Related Condition Support Groups

Crohn's Disease

Related Drug Support Groups

metronidazole, Humira, Flagyl, Remicade, Asacol, Tysabri, Imuran, sulfasalazine, budesonide, view more... Pentasa, Cimzia, azathioprine, Metro, Entocort EC, mercaptopurine, mesalamine, Entyvio, infliximab, Flagyl IV, adalimumab, Asacol HD, natalizumab, Inflectra, vedolizumab, Azasan, Purinethol, certolizumab, Renflexis, Amjevita, Canasa Pac, Protostat, Metro IV, Flagyl 375, Metryl, FIV-ASA, Salofalk, Mesasal Enteric Coated